Literature DB >> 26167561

Is periconceptional opioid use safe?

Felix Chan, Gideon Koren.   

Abstract

QUESTION: A patient in my practice who takes buprenorphine for chronic pain would like to conceive. Is it safe for her to continue taking her medication? ANSWER: The literature regarding periconceptional opioid use is conflicted as to whether opioids pose an elevated risk of birth defects. Confounding factors such as socioeconomic status, stress, and alcohol consumption might play a role. The first trimester of pregnancy is the critical period of development for many organ systems in the embryo. A chemical or environmental insult is more likely to produce major congenital malformations such as neural tube defects or mental retardation if it occurs within this window. Medical practitioners should judiciously consider a risk-benefit analysis before making their decisions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26167561      PMCID: PMC4430058     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  11 in total

1.  Maternal treatment with opioid analgesics and risk for birth defects.

Authors:  Geert W 't Jong; Gideon Koren
Journal:  Am J Obstet Gynecol       Date:  2011-06-15       Impact factor: 8.661

2.  Maternal treatment with opioid analgesics and risk for birth defects: additional considerations.

Authors:  Hendrée E Jones; Lauren M Jansson; Kevin E O'Grady
Journal:  Am J Obstet Gynecol       Date:  2011-04-24       Impact factor: 8.661

3.  Periconception warnings about prescribing opioids.

Authors:  William F Rayburn; Matthew C Brennan
Journal:  Am J Obstet Gynecol       Date:  2011-04       Impact factor: 8.661

4.  Maternal treatment with opioid analgesics and risk for birth defects.

Authors:  Cheryl S Broussard; Sonja A Rasmussen; Jennita Reefhuis; Jan M Friedman; Michael W Jann; Tiffany Riehle-Colarusso; Margaret A Honein
Journal:  Am J Obstet Gynecol       Date:  2011-02-23       Impact factor: 8.661

5.  Neonatal drug withdrawal.

Authors:  Mark L Hudak; Rosemarie C Tan
Journal:  Pediatrics       Date:  2012-01-30       Impact factor: 7.124

6.  Maternal illness, including fever and medication use as risk factors for neural tube defects.

Authors:  G M Shaw; K Todoroff; E M Velie; E J Lammer
Journal:  Teratology       Date:  1998-01

7.  Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain.

Authors:  Emilse S Sanchez; John W Bigbee; Wambura Fobbs; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2008-07       Impact factor: 7.452

Review 8.  The opioid-exposed newborn: assessment and pharmacologic management.

Authors:  Lauren M Jansson; Martha Velez; Cheryl Harrow
Journal:  J Opioid Manag       Date:  2009 Jan-Feb

9.  Periconceptional use of opioids and the risk of neural tube defects.

Authors:  Mahsa M Yazdy; Allen A Mitchell; Sarah C Tinker; Samantha E Parker; Martha M Werler
Journal:  Obstet Gynecol       Date:  2013-10       Impact factor: 7.661

10.  Effects of codeine on pregnancy outcome: results from a large population-based cohort study.

Authors:  Kateřina Nezvalová-Henriksen; Olav Spigset; Hedvig Nordeng
Journal:  Eur J Clin Pharmacol       Date:  2011-06-09       Impact factor: 2.953

View more
  3 in total

1.  Neuropathic Pain due to Neurofibromatosis Treated With Transcutaneous Electrical Nerve Stimulation in a Pregnant Patient: A Case Report.

Authors:  Victor Caño Silva; Ancor Serrano Afonso
Journal:  A A Pract       Date:  2019-11-01

2.  Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study.

Authors:  Alexa C Bowie; Martha M Werler; Maria P Velez; Wenbin Li; Andi Camden; Astrid Guttmann; Susan B Brogly
Journal:  CMAJ       Date:  2022-02-07       Impact factor: 8.262

3.  Prenatal Opioid Analgesics and the Risk of Adverse Birth Outcomes.

Authors:  Susan B Brogly; Maria P Velez; Martha M Werler; Wenbin Li; Andi Camden; Astrid Guttmann
Journal:  Epidemiology       Date:  2021-05-01       Impact factor: 4.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.